Novo Nordisk Cuts Wegovy Cash Price to $349 Monthly in Canada

New Pricing Structure

The pharmaceutical company announced the reduced pricing structure for cash-paying patients in Canada, implementing the change months ahead of its original timeline. This represents a significant shift in the company's pricing strategy as generic competition approaches.

Previous cash prices for Wegovy in Canada typically ranged between $400 and $570 per month, making the new $349 price point a reduction of approximately 13-39% depending on the specific dosage and pharmacy.

Market Context

The price reduction comes as Health Canada continues reviewing nine generic semaglutide applications following the January 4, 2026 patent expiration. Companies including Sandoz Canada, Apotex, and Teva are among those seeking approval for generic versions of the active ingredient found in both Ozempic and Wegovy.

Current list prices for related medications include:

• Ozempic: approximately $2,899 annually before pharmacy markups
• Wegovy: estimated $5,000 annually based on maintenance dosing
• Generic projections: potentially $28-$140 annually when approved

Insurance Coverage Considerations

The new cash price may impact patients without insurance coverage or those with limited pharmaceutical benefits. Many Canadian employer drug plans and provincial programs have varying coverage policies for GLP-1 medications, with some requiring prior authorization or step therapy protocols.

Patients should consult their insurance coverage checker to understand their specific benefits and out-of-pocket costs under current plans.

Regulatory Status

Wegovy maintains its Health Canada approval status with current Notice of Compliance documentation. The medication is available in multiple strength formulations through Canadian pharmacies including Shoppers Drug Mart, Costco, and Rexall.

Health Canada's generic semaglutide tracker continues monitoring the nine pending applications, with approval timelines extending into mid-2026 based on current regulatory review schedules.

Market Impact

The pricing adjustment reflects broader pharmaceutical industry responses to pending generic competition. Similar medications including Mounjaro from Eli Lilly have also seen strategic pricing modifications in various markets.

Industry analysts note that brand manufacturers typically adjust pricing structures when facing imminent generic competition to maintain market share during transition periods.

Additional Information

Patients seeking current pricing information can verify costs directly with participating Canadian pharmacies. Pricing may vary by location, pharmacy, and specific dosage requirements.

For comprehensive information about GLP-1 medications and pricing, patients can reference our FAQ section for additional guidance on navigating medication costs and coverage options.